Stapled Peptide SM3-4 Kills Cancer Cells by Blocking Both MDM2 and MDMX at Low Doses | Research

The takeaway

A stapled peptide (SM3-4) designed to dual-target MDM2 and MDMX induced tumor cell apoptosis at low micromolar concentrations with enhanced helicity, proteolysis resistance, and cell-penetrating ability compared to straight-chain peptides.

Low μM tumor cell killing
Stapled peptide SM3-4 induced cancer cell death by simultaneously blocking both p53 inhibitors (MDM2 and MDMX)

What the researchers found

Stapled peptide SM3-4 dual-targeted MDM2/MDMX, induced tumor cell apoptosis at low μM concentrations in vitro, showed significantly increased helicity compared to linear peptides, and demonstrated that enhanced staple activity correlates with helicity.

Why it matters

MDM2/MDMX are among the most important cancer drug targets — blocking them reactivates p53 in the majority of tumors that retain wild-type p53. Stapled peptides solve the key challenges of peptide drugs (stability and cell entry), making them viable cancer therapeutics.

The numbers in context

SM3-4 induced apoptosis at low μM concentrations. Significantly enhanced helix compared to linear counterparts.

How the study worked

Designed and synthesized a series of PMI-M3-based stapled peptides with dual MDM2/MDMX targeting. Compared helicity, proteolysis resistance, cell penetration, and anti-tumor activity against straight-chain peptide controls. Tumor cell apoptosis tested in vitro.

Who was studied

Cancer cell lines

What this study cannot tell us

In vitro study only — tumor cell killing in culture doesn't guarantee efficacy in animals or humans. The specific tumor cell lines tested weren't detailed. Pharmacokinetics, biodistribution, and in vivo anti-tumor efficacy haven't been assessed.

How to read the evidence

Preliminary evidence from in vitro peptide design and cell culture testing. No animal or human data available.

When this study was published

Published in 2024; represents current stapled peptide drug design for cancer.

The bigger picture

Stapled peptides are an exciting drug class that bridges the gap between small molecules and biologics. Several stapled peptides targeting p53-MDM2 are in clinical trials. SM3-4's dual MDM2/MDMX targeting could be superior to MDM2-only approaches, since MDMX upregulation is a common resistance mechanism.

Questions still open

Does SM3-4 show anti-tumor efficacy in mouse cancer models?
What is the selectivity of SM3-4 — does it spare normal cells that express p53?
Could SM3-4 be combined with existing cancer treatments for synergistic effects?

Common questions

What are stapled peptides?

Stapled peptides have a chemical 'staple' (usually a hydrocarbon bridge) that locks the peptide into a helical shape. This makes them more resistant to degradation by enzymes, better able to penetrate cell membranes, and more stable than regular peptides — solving the main problems that prevent peptides from being effective drugs.

What are MDM2 and MDMX and why target them?

MDM2 and MDMX are proteins that disable p53, the body's most important tumor suppressor. In most cancers, p53 is present but silenced by MDM2/MDMX. Blocking both simultaneously reactivates p53, which can trigger cancer cell death. Dual targeting is important because tumors can escape MDM2-only blockade by upregulating MDMX.

Read the original research

Study on the design, synthesis, and activity of anti-tumor staple peptides targeting MDM2/MDMX.

Frontiers in chemistry, 12, 1403473

View on PubMed ↗Publisher’s paper ↗

Citation

Yang, Jian; Liao, Xiufei; Hu, Damin; Mo, Jinqiu; Gao, Xiurong; Liao, Hongli. (2024). Study on the design, synthesis, and activity of anti-tumor staple peptides targeting MDM2/MDMX.. Frontiers in chemistry, 12, 1403473. https://doi.org/10.3389/fchem.2024.1403473